Levodopa/carbidopa intestinalis gél kezelés hatása az életmino{combining double acute accent}ségre

Translated title of the contribution: The impact of levodopa-carbidopa intestinal gel on health-related quality of life in Parkinson's disease

N. Kovács, Zsuzsanna Aschermann, Péter Ács, Edit Bosnyák, Gabriella Deli, J. Janszky, S. Komoly

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background - The levodopa/carbidopa intestinal gel (LCIG) therapy can improve the severe fluctuations associated with advanced Parkinson's disease (PD). Our aim was to assess the improvement in the health related quality of life of PD patients treated with LCIG at University of Pécs. Methods - Eight PD patients were evaluated (age: 68.1±4.4 years, disease duration: 14,5±6,2 years, duration of fluctuations: 8.9±3.1 years). Before the initiation of LCIG treatment and 6 and 12 months later, the health-related quality of life (PDQ-39 and EQ-5D-5L), severity of PD-related symptoms (MDS-UPDRS, Hoehn-Yahr Scale, Clinical Global Improvement - Severity) and major non-motor symptoms (PD Sleep Scale 2nd version: PDSS-2, Epworth Scale and Beck Depression Inventory: BDI) were assessed. Results - Health-related quality life improved after LCIG treatment measured by both EQ-5D-5L (from 0.257 to 0.662, p=0.009) and PDQ-39 (from 34 to 26 points, p=0.038). Meanwhile PD-related symptoms (MDS-UPDRS total score: from 105 points to 68 points, p

Original languageHungarian
Pages (from-to)245-250
Number of pages6
JournalIdeggyógyászati szemle
Volume67
Issue number7-8
Publication statusPublished - Jul 30 2014

Fingerprint

Parkinson Disease
Gels
Quality of Life
levodopa drug combination carbidopa
Sleep
Therapeutics
Depression
Equipment and Supplies
propylene diquat

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Levodopa/carbidopa intestinalis gél kezelés hatása az életmino{combining double acute accent}ségre. / Kovács, N.; Aschermann, Zsuzsanna; Ács, Péter; Bosnyák, Edit; Deli, Gabriella; Janszky, J.; Komoly, S.

In: Ideggyógyászati szemle, Vol. 67, No. 7-8, 30.07.2014, p. 245-250.

Research output: Contribution to journalArticle

Kovács, N. ; Aschermann, Zsuzsanna ; Ács, Péter ; Bosnyák, Edit ; Deli, Gabriella ; Janszky, J. ; Komoly, S. / Levodopa/carbidopa intestinalis gél kezelés hatása az életmino{combining double acute accent}ségre. In: Ideggyógyászati szemle. 2014 ; Vol. 67, No. 7-8. pp. 245-250.
@article{e060b1e193d3403ab17b00cc39b32325,
title = "Levodopa/carbidopa intestinalis g{\'e}l kezel{\'e}s hat{\'a}sa az {\'e}letmino{combining double acute accent}s{\'e}gre",
abstract = "Background - The levodopa/carbidopa intestinal gel (LCIG) therapy can improve the severe fluctuations associated with advanced Parkinson's disease (PD). Our aim was to assess the improvement in the health related quality of life of PD patients treated with LCIG at University of P{\'e}cs. Methods - Eight PD patients were evaluated (age: 68.1±4.4 years, disease duration: 14,5±6,2 years, duration of fluctuations: 8.9±3.1 years). Before the initiation of LCIG treatment and 6 and 12 months later, the health-related quality of life (PDQ-39 and EQ-5D-5L), severity of PD-related symptoms (MDS-UPDRS, Hoehn-Yahr Scale, Clinical Global Improvement - Severity) and major non-motor symptoms (PD Sleep Scale 2nd version: PDSS-2, Epworth Scale and Beck Depression Inventory: BDI) were assessed. Results - Health-related quality life improved after LCIG treatment measured by both EQ-5D-5L (from 0.257 to 0.662, p=0.009) and PDQ-39 (from 34 to 26 points, p=0.038). Meanwhile PD-related symptoms (MDS-UPDRS total score: from 105 points to 68 points, p",
keywords = "Parkinson's disease, Quality, Rating scales",
author = "N. Kov{\'a}cs and Zsuzsanna Aschermann and P{\'e}ter {\'A}cs and Edit Bosny{\'a}k and Gabriella Deli and J. Janszky and S. Komoly",
year = "2014",
month = "7",
day = "30",
language = "Hungarian",
volume = "67",
pages = "245--250",
journal = "Ideggyogyaszati Szemle",
issn = "0019-1442",
publisher = "Ifjusagi Lap-es Konyvkiado Vallalat",
number = "7-8",

}

TY - JOUR

T1 - Levodopa/carbidopa intestinalis gél kezelés hatása az életmino{combining double acute accent}ségre

AU - Kovács, N.

AU - Aschermann, Zsuzsanna

AU - Ács, Péter

AU - Bosnyák, Edit

AU - Deli, Gabriella

AU - Janszky, J.

AU - Komoly, S.

PY - 2014/7/30

Y1 - 2014/7/30

N2 - Background - The levodopa/carbidopa intestinal gel (LCIG) therapy can improve the severe fluctuations associated with advanced Parkinson's disease (PD). Our aim was to assess the improvement in the health related quality of life of PD patients treated with LCIG at University of Pécs. Methods - Eight PD patients were evaluated (age: 68.1±4.4 years, disease duration: 14,5±6,2 years, duration of fluctuations: 8.9±3.1 years). Before the initiation of LCIG treatment and 6 and 12 months later, the health-related quality of life (PDQ-39 and EQ-5D-5L), severity of PD-related symptoms (MDS-UPDRS, Hoehn-Yahr Scale, Clinical Global Improvement - Severity) and major non-motor symptoms (PD Sleep Scale 2nd version: PDSS-2, Epworth Scale and Beck Depression Inventory: BDI) were assessed. Results - Health-related quality life improved after LCIG treatment measured by both EQ-5D-5L (from 0.257 to 0.662, p=0.009) and PDQ-39 (from 34 to 26 points, p=0.038). Meanwhile PD-related symptoms (MDS-UPDRS total score: from 105 points to 68 points, p

AB - Background - The levodopa/carbidopa intestinal gel (LCIG) therapy can improve the severe fluctuations associated with advanced Parkinson's disease (PD). Our aim was to assess the improvement in the health related quality of life of PD patients treated with LCIG at University of Pécs. Methods - Eight PD patients were evaluated (age: 68.1±4.4 years, disease duration: 14,5±6,2 years, duration of fluctuations: 8.9±3.1 years). Before the initiation of LCIG treatment and 6 and 12 months later, the health-related quality of life (PDQ-39 and EQ-5D-5L), severity of PD-related symptoms (MDS-UPDRS, Hoehn-Yahr Scale, Clinical Global Improvement - Severity) and major non-motor symptoms (PD Sleep Scale 2nd version: PDSS-2, Epworth Scale and Beck Depression Inventory: BDI) were assessed. Results - Health-related quality life improved after LCIG treatment measured by both EQ-5D-5L (from 0.257 to 0.662, p=0.009) and PDQ-39 (from 34 to 26 points, p=0.038). Meanwhile PD-related symptoms (MDS-UPDRS total score: from 105 points to 68 points, p

KW - Parkinson's disease

KW - Quality

KW - Rating scales

UR - http://www.scopus.com/inward/record.url?scp=84906219931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906219931&partnerID=8YFLogxK

M3 - Article

C2 - 25509365

AN - SCOPUS:84906219931

VL - 67

SP - 245

EP - 250

JO - Ideggyogyaszati Szemle

JF - Ideggyogyaszati Szemle

SN - 0019-1442

IS - 7-8

ER -